Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Biogen Inc    BIIB   US09062X1037

BIOGEN INC (BIIB)

155
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

01/28/2013 | 07:13am US/Eastern
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on BIOGEN INC
07:32a BIOGEN : PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annu..
07:31a BIOGEN : International Survey from Biogen Identifies Opportunities for Improving..
04/20 BIOGEN : TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficac..
04/19DJMARKET SNAPSHOT : Peak Earnings Week To Follow Big Global Selloff
04/14 BIOGEN : Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrati..
04/08 MERCK KGAA : EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice Pres..
04/07 BIOGEN : Data at AAN Annual Meeting Underscore Commitment to Advancing Patient C..
04/05DJSuspect in Body-Parts Discovery to Appear in Court Monday -- Update
04/01 BIOGEN : to Report First Quarter 2015 Financial Results on April 24, 2015
04/01 BIOGEN : EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice Presiden..
Advertisement
Chart
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF